


## H-Glu-OtBu

<b>Cat. No.:</b>	HY-W018154		
<b>CAS No.:</b>	45120-30-7		
<b>Molecular Formula:</b>	C <sub>9</sub> H <sub>17</sub> NO <sub>4</sub>		
<b>Molecular Weight:</b>	203.24		
<b>Target:</b>	ADC Linker; PROTAC Linkers		
<b>Pathway:</b>	Antibody-drug Conjugate/ADC Related; PROTAC		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 10 mg/mL (49.20 mM; ultrasonic and warming and heat to 60°C)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	4.9203 mL	24.6015 mL	49.2029 mL
5 mM	0.9841 mL	4.9203 mL	9.8406 mL
10 mM	0.4920 mL	2.4601 mL	4.9203 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

H-Glu-OtBu is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). H-Glu-OtBu is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[2]

#### IC<sub>50</sub> & Target

Non-cleavable Linker

#### In Vitro

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker<sup>[1]</sup>. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA